Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33988710.
- Also identified by DOI 10.1001/jamanetworkopen.2021.10079 and PMC identifier 8122227.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cross-sectional study assesses the availability of the direct oral anticoagulant reversal agents idarucizumab and andexanet alfa in US hospitals.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Anticoagulant Reversal Agents
- Factor Xa
- Hospitals
- Recombinant Proteins